NEW YORK (GenomeWeb) – Dow AgroSciences and Critical Path Services today announced a license agreement for patents related to plant proteomics.
Under the terms of the agreement, Critical Path will receive a non-exclusive license to intellectual property held by Dow AgroSciences, a wholly-owned subsidiary of Dow Chemical, including Plextein, a high-throughput method for multiplex detection of proteins in plants using liquid chromatography with tandem mass spectroscopy.
"Plextein has the potential to accelerate the discovery and development of novel plant traits by simplifying the analysis of complex samples, which ultimately benefits farmers with new products," Tom Meade, Dow AgroSciences Global Seeds Discovery Leader, said in a statement.
Critical Path CEO Julie Eble added that Plextein is a "very powerful tool for protein quantitation in situations where an ELISA approach is not viable. With access to Dow AgroSciences' Plextein technology, we can address multiple proteins in a single run for clients facing this common situation."
Last month, Dow AgroScience signed a deal to license zinc finger nuclease-based genome editing technology to the Institute of Crop Sciences at the Chinese Academy of Agricultural Sciences.